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ABSTRACT
Germline pathogenic variants in the BRCA2 gene are associated with a cumulative 
high risk of breast/ovarian cancer. Several BRCA2 variants result in complete loss 
of the exon-3 at the transcript level. The pathogenicity of these variants and the 
functional impact of loss of exon 3 have yet to be established.
As a collaboration of the COVAR clinical trial group (France), and the ENIGMA 
consortium for investigating breast cancer gene variants, this study evaluated 8 
BRCA2 variants resulting in complete deletion of exon 3. Clinical information for 39 
families was gathered from Portugal, France, Denmark and Sweden. Multifactorial 
likelihood analyses were conducted using information from 293 patients, for 7 out 
of the 8 variants (including 6 intronic). For all variants combined the likelihood ratio 
in favor of causality was 4.39*1025. These results provide convincing evidence for 
the pathogenicity of all examined variants that lead to a total exon 3 skipping, and 
suggest that other variants that result in complete loss of exon 3 at the molecular 
level could be associated with a high risk of cancer comparable to that associated 
with classical pathogenic variants in BRCA1 or BRCA2 gene. In addition, our functional 
study shows, for the first time, that deletion of exon 3 impairs the ability of cells to 
survive upon Mitomycin-C treatment, supporting lack of function for the altered BRCA2 
protein in these cells.
Finally, this study demonstrates that any variant leading to expression of only 
BRCA2 delta-exon 3 will be associated with an increased risk of breast and ovarian 
cancer.
INTRODUCTION
The BRCA2 gene (MIM#600185) is a tumor 
suppressor gene that codes for a 3,418 amino-acid 
protein discovered in 1995 [1]. BRCA2 is involved in the 
maintenance of genome integrity by means of two main 
functions: DNA repair by homologous recombination and 
stabilization of replication forks under replication stress 
[2–7]. Pathogenic germline BRCA2 variants predispose to 
high risk of breast and ovarian cancer and are associated 
with the Hereditary Breast and Ovarian Cancer syndrome 
(HBOC) [8, 9].
The cancer risk for BRCA2 pathogenic variant 
carriers is 55% for breast cancer, 16.5% for ovarian cancer, 
and 62% for contralateral breast cancer [10]. The variants 
identified in women are mostly classified as pathogenic 
when they lead to a premature translation termination 
(premature stop codon). However, variant classification is 
complicated toward the related risk of cancer when the 
molecular or functional effect of a variant is unclear [11]. 
A recent study showed that the cancer risk of pathogenic 
variant carriers in the different regions of BRCA2 is not 
similar. BRCA2 pathogenic variants localized in 5’ (5’ 
to c.2830) and 3’ (3’ to c.6402) regions were associated 
with a significant higher breast cancer risk compared with 
pathogenic variants within the central region [12].
To date, several functional domains have been 
described in BRCA2 including the C-terminal DNA binding 
domain [13]; the BRC repeats in the central region of the 
protein have a well-established function in the interaction 
with RAD51 [14–16]. The N-terminal region has been less 
extensively explored, but it has recently been shown to 
contain a second DNA binding domain [17]. The N-terminal 
region of BRCA2 also comprises exon 3, amino acids 23 
to 105. According to the literature, exon 3 is found to be 
bipartite with a primary activating region (PAR: aa 23-
60) and an auxiliary activating region (AAR: aa 60-105). 
The AAR region has little homology with c-Jun [18] and 
would be responsible for a kinase activity different from 
that of c-Jun or independently of the JNK signaling pathway 
[19, 20]. Milner et al. have shown that these residues bind 
specifically as a kinase. In addition, the team of Lin et al. 
tested the possible phosphorylation of BRCA2 by PLK1 
in this region [21]. The primary activating region (PAR) 
has an activation capacity and is responsible for protein-
protein interaction. These residues are involved in an 
interaction with EMSY, but with no obvious function [22]. 
EMSY has endogenous transcriptional repressor activity, 
and participates in DNA damage foci formation. In 2002, 
Preobrazhenska et al. showed that BRCA2 (exon 3) is also 
a Smad-interacting protein which synergizes with Smad3 in 
activation of gene expression [23].
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Most interestingly, the PAR domain also interacts 
with the PALB2 protein (Partner and localizer of BRCA2) 
[24]. PALB2 is involved in DNA repair by homologous 
recombination and forms a complex with BRCA1 and 
BRCA2 [25].
In the literature, several variants within exon 3 
have been described with partial splicing effect (c.68-
7T>A, c.68-7_8delinsAA, c.68-7delT) or total splicing 
effect (c.316+4del, c.156_157insAlu, for example) and 
considered as neutral (c.68-7T>A, c.125A>G) or causal 
(c.156_157insAlu) [26, 27]. Furthermore, although point 
mutations and large rearrangements in the BRCA2 gene 
giving rise to exon 3 skipping at the mRNA level might 
be associated to the abnormal phenotype in breast/ovarian 
cancer families, the skipping of exon 3 does not alter the 
reading frame, and the RAD51 binding sites, nuclear 
localization signals in the 3’ region of BRCA2 or other 
functional domains of the protein still remain intact. 
Therefore, the heterogeneity of splicing effects with the 
expression of low quantity of full transcript has shed the 
doubt on the pathogenicity. Several variants of BRCA2 are 
known to result in total loss of exon 3 at the transcript 
level. For example, the variant with the Alu insertion 
in the middle of exon 3 (c.156_157insAlu) have been 
reported in families of Portuguese ancestry and could 
be due to the existence of co-founding variants related 
to this insertion, as all families have the same ancestry 
[27–29]. The c.68-?_316+?del and c.316+4del (previously 
reported as c.316+3delA) variants with loss of exon 3 tend 
to increase breast cancer risk in the affected families [26]. 
For those variants in these studies, the number of families 
and variants were not sufficient for detailed cancer risk 
assessment, using co-segregation and other clinical 
information.
Moreover, the functional role of the affected delta-3 
BRCA2 protein domain has not been established and the 
existence of a stable delta-3 BRCA2 protein, although 
theoretically possible, has not been proven. Several 
variants lead to a complete in frame deletion of exon 3 
has been identified in different countries. A study of 
the impact of variants leading to transcripts that encode 
full delta-3 BRCA2 was conducted in France within 
the framework of the COsegregation of VARiants in 
the BRCA1/2 Genes (COVAR) clinical trial [30]. In 
parallel, the ENIGMA (Evidence-Based Network for the 
Interpretation of Germline Mutant Alleles) international 
consortium (including members of COVAR), which is 
an initiative to evaluate risk and determine the clinical 
significance of unclassified BRCA1, BRCA2 and other 
breast cancer susceptibility genes variants, has conducted 
a collaborative study of known or potentially spliceogenic 
BRCA2 variants [31]. To increase the statistical power 
and reduce the risk of population bias we have included 
families from both initiatives in the present analysis.
This study addressed several questions related to 
eight BRCA2 variants reported to cause complete loss of 
exon 3 at the transcriptional level that are expected to lead 
to a delta-3 protein. First, we selected and confirmed the 
variants exclusively leading to full skipping of this exon 
to avoid any biais related to partial expression. Second, we 
performed functional analysis to determine the impact of a 
delta-exon-3 BRCA2 protein on BRCA2 function. Finally, 
we estimated for each variant the causality and probability 
of being deleterious using multifactorial likelihood 
analysis including, in addition to segregation data, other 
clinical estimates of variant pathogenicity.
RESULTS
Selection of variants to address the pathogenic 
nature of complete loss of BRCA2 exon 3
In this study, we selected a total of 8 BRCA2 variants 
including 6 genetic changes for which there was evidence 
from patient RNA data that they were associated with total 
in-frame exon 3 skipping (Supplementary Table 1A). In 
addition, we included 2 other variants identified in our 
cohort located at the invariant positions of the 5’ splice 
site of BRCA2 exon 3 (IVS3+1/+2), expected to cause the 
same effect.
Confirmation of full exon skipping induced by 
variants mapping at the 5’ splice site of BRCA2 
intron 3
To evaluate the impact on splicing of the 5 
variants located at the 5’ splice site of BRCA2 exon 3, 
we performed a cell-based minigene assay. As shown in 
Figure 1, the pCAS2-BRCA2 exon 3 wild-type minigene 
led to the major production of transcripts containing 
exon 3 (99% inclusion), whereas the minigene carrying 
the BRCA2 c.68-7T>A variant, used here as a control, 
induced weak exon skipping (7%), as previously shown 
in patient RNA [26]. In contrast, BRCA2 c.316+1G>T 
and c.316+4del were responsible of total exon 3 skipping 
(100%), as quantified by fluorescent RT-PCR. The 3 
other intronic variants tested, BRCA2 c.316+2T>C, 
c.316+5G>A and c.316+5G>C, induced major, quasi-
complete, exon 3 skipping (respectively, 97%, 94% and 
95%). These results are in agreement with patient RNA 
data (Supplementary Table 1A) and/or in silico predictions 
(Supplementary Table 1B).
Impact in the function of BRCA2
To investigate the functional impact of the complete 
deletion of exon 3, we generated a cDNA expressing 
construct carrying this deletion. As expected, we found 
that GFP-MBP-BRCA2 WT fully complemented brca2-
deficient hamster cells (VC8) [32]. In contrast, the 
complete deletion of exon 3 of BRCA2 rendered cells 
hypersensitive to Mitomycin C (MMC) treatment to 
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Figure 1: A minigene splicing assay confirms that variants located at the 5’ splice site of BRCA2 exon 3 induce drastic 
exon skipping. (A) Structure of the pCAS2-BRCA2-exon 3 minigene used in the minigene splicing assay. The grey arrow indicates the 
CMV promoter, boxes represent exons, lines in between indicate introns, and arrows under the exons represent primers used in RT-PCR 
reactions. The positions of the variants analyzed in the minigene assay are also indicated. The minigenes were generated by inserting a 
genomic fragment containing BRCA2 exon 3 and part of flanking intronic sequences into the intron of pCAS2 (either by using the proband’s 
gDNA as template or by introducing the variants into the minigenes by site-directed mutagenesis). WT and mutant constructs, as indicated, 
were then transfected into HeLa cells and the minigene transcripts were analyzed by RT-PCR, as described in Materials and Methods. (B) 
Analysis of the splicing pattern of the pCAS2-BRCA2-exon 3 minigenes carrying the variants of interest. BRCA2 c.68-7T>A was used as 
control. The image shows the results of a representative experiment, in which the RT-PCR products were separated on a 2.5% agarose gel 
stained with ethidium bromide and visualized by exposure to ultraviolet light. M, size marker (100 bp DNA ladder, New England Biolabs). 
The identities of the two major RT-PCR products, with or without exon 3, are indicated on the right. (C) Representative results from 
fluorescent RT-PCR reactions (equivalent to those shown in B) performed by using a fluorescent forward primer and then separated under 
denaturing conditions by capillary electrophoresis on an automated sequencer. The identities of the RT-PCR products are shown above the 
peaks. (D) Level of exon 3 skipping observed in the minigene assay as determined by fluorescent RT-PCR (variants displayed in the same 
order as in B). Results are shown as the average of three independent experiments and are expressed as percentage of exon skipping (exon 
skipping product x 100/total transcripts).
Oncotarget17338www.oncotarget.com
the same level as the known pathogenic BRCA2 variant 
D2723H (c.8167G>C, p.Asp2723His, exon 18) or Brca2-
deficient cells (Figure 2A). The deletion of exon 3 did 
not affect the translation and stability of the protein, as it 
was readily detected by Western Blot (Figure 2B). These 
results strongly suggest that the region encoded by exon 
3 is necessary to restore cell viability following MMC-
induced DNA damage.
Causality score from multifactorial likelihood 
analysis, including segregation data
Multifactorial likelihood analyses were conducted 
using information from 293 patients (194 confirmed as 
carriers of the variant under study) in 26 families. Variants 
were categorized based on the final posterior probability, 
according to the classification system for sequence 
variants proposed by the 2008 IARC working group on 
unclassified genetic variants [33].
The co-segregation analysis for variants BRCA2 
c.316+5G>C and c.156_157insAlu were the most 
informative, with 10 and 13 informative families, 
respectively, and with a substantial segregation likelihood 
score of 14544.25 and 6.4124x1012 respectively (each 
with a highly informative family, Figure 3). BRCA2 c.68-
?_316+?del also presented a strong segregation likelihood 
score (1393.30) from only one family with 15 variant 
carriers among 19 individuals tested. LR from segregation 
Figure 2: Hypersensitivity of cells exposed to Mitomycin C (MMC) expressing BRCA2 cDNA carrying Δexon 3. (A) 
Clonogenic survival assay of VC8 cells (Brca2 -/-) expressing human BRCA2 wild-type (WT), D2723H (c.8167G>C, exon 18) missense 
mutation or Δexon 3 in response to the indicated concentrations of MMC. Error bars, S.D. (n=3). (B) Western blot showing GFP-BRCA2 
protein immunoprecipitated from the cell population used for seeding for the clonogenic survival assay (A). StainFree imaging of the gel 
before transfer was used as a loading control (only a cropped image of the gel is shown).
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data alone was in favor of pathogenicity for all other 
variants with data: c.277_317-726delinsCCAT (19.35), 
c.316+5G>A (3.69) and c.316+4del (86.77).
Breast tumor pathology data were available for 
some variant carriers (Supplementary Table 2). The tumor 
was estrogen receptor-positive and progesterone receptor-
negative. For c.316+5G>A, the proband presented breast 
cancer diagnosed at the age of 30 years that was estrogen 
receptor-positive. For c.316+5G>C, we present pathology 
data for 8 patients: age of onset of breast cancer was 
between 25 and 55 years, with minimum grade 2 and 
positive estrogen receptor status in almost all cases (6/7). 
For c.156_157insAlu, pathology data were available for 
25 patients: ages of onset of breast cancer were between 
28 and 66 years and estrogen receptor status was positive 
for almost all tumors. LR based on pathology information 
was higher than 1 for all variants for which relevant 
information was available.
Pathogenicity was assessed for each variant 
individually, and also for all 7 variants for which 
information was available, as they were considered to 
have resulted from the same RNA and protein event. As 
shown in Table 1, when considering variants individually, 
three variants had posterior probabilities >0.99 that 
categorized them as pathogenic (class 5) providing 
convincing evidence that these variants are associated with 
a cancer risk equivalent to the average (mostly truncating) 
pathogenic variants in BRCA2. For all variants combined, 
the likelihood ratio in favour of causality was 4.39*1025, 
and the posterior probability of pathogenicity was 1.00.
DISCUSSION
Clinical classification of sequence variants is often 
limited by the small number of families or the lack of 
clinical information. This study shows the potential of 
combined analysis of several variants causing the same 
functional effect to increase the power of multifactorial 
likelihood analysis, in particular co-segregation data. In 
this study, we combined all known variants resulting in 
complete loss of exon 3, including 5 intronic changes 
directly affecting the splice donor site as confirmed by 
splicing assay. This hypothesis was first established with 
the analysis of the large rearrangement of exon 3 [26]; 
Figure 3: Pedigrees of families with BRCA2 c. 316+5G>C (A) and c.156_157insAlu (B) variants. Circles indicate females 
and squares indicate males, in bold relatives with mutated genetic status known but not affected. Slashes indicate death. The proband is 
indicated by an arrow. Current ages or age at death and age at cancer diagnosis are listed below each individual, together with genetic status 
when known.
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however, the classification of complete deletions of exon 3 
in BRCA2 in the clinical setting has been controversial [26, 
28, 29, 34–38]. In this study, we definitively prove that a 
full total deletion of exon 3 of BRCA2 is pathogenic.
Indeed, in this study, we validate the full in-frame 
exon 3 skipping for six BRCA2 variants with the minigene 
approach avoiding any ambiguity on a partial expression 
of a full transcript. This approach was required to gather 
several variants with a putative similar impact on splicing 
and to distinguish those variants to those on the intron 2 
(c.68-7A>T).
Then this study presents results from multifactorial 
likelihood analysis of six out of eight BRCA2 variants 
proven to lead to a full in-frame exon 3 skipping at the 
transcriptional level, including co-segregation analysis 
of multiple families (c.68-?_316+?del, c.156_157insAlu, 
c.316+1G>T, c.316+4del, c.316+5G>A, c.316+5G>C). 
There was sufficient evidence to classify individually three 
variants as pathogenic (Class 5). Notably, the likelihood 
ratio of causality from segregation data alone was 1393:1 
from a single family carrying c.68-?_316+?del, 14544:1 
for 12 families carrying c.316+5G>C, and 6.4x1012 for 
13 families carrying c.156_157insAlu. Another variant 
(c.316+4del) had sufficient information available to 
place it as likely pathogenic (Class 4). All evidence from 
segregation and pathology data for individual variants, 
irrespective of their individual classification, was in 
favor of pathogenicity. The likelihood ratio in favor of 
causality was 4.39*1025, and the posterior probability of 
pathogenicity was 1.00 for all variants combined. These 
results provide convincing evidence for the pathogenicity 
of all seven variants that lead to complete deletion of exon 
3, and suggest that other variants that result in complete 
loss of exon 3 at the molecular level will be associated 
with a high risk of cancer comparable to other classical 
pathogenic variants in BRCA2 (largely truncating), 
including c.316+2G>T. The pathology of consecutive 
breast cancers related to those variants were estrogen 
receptor-positive as typically described for BRCA2 breast 
tumors (Supplementary Table 2; 29/35 ER-positive, 32/35 
PR-positive, 4/18 HER2-positive, 10/25 grade 2) [39]. 
The variant c.277_317-726delinsCCAT from Nordling 
et al. presented one family with pathology data for one 
carrier with invasive cancer of the left breast and multiple 
axillary and supraclavicular node metastases at the age of 
41 years [32]. These findings are of direct relevance for 
counseling and management of individuals found to carry 
these variants.
Importantly, our clinical analysis is fully supported 
by functional assays demonstrating that ectopically 
expressed BRCA2 transcripts lacking exon 3 confer 
hypersensitivity to DNA damage (MMC treatment). 
Our functional study shows, for the first time, that 
deletion of exon 3 impairs the ability of cells to survive 
Table 1: Classification based on multifactorial likelihood analysis for BRCA2 variants leading to exon 3 deletion at 
the mRNA level
HGVS DNA 
nomenclature c.
RNA 
impact
Number 
of 
families
Number of 
families for 
cosegregation 
analysis
Number of 
relatives for 
cosegregation 
analysis 
(carriers)
LR 
cosegregation
LR 
Pathology
Combined 
LR 
causality
Prior 
probability 
[67]
Posterior 
probability
Class
c.68_316del full 
skipping
1 1 19 (15) 1393,30 - 1393,30 0,5 0,999282796 Class 5
c.156_157insAlu full 
skipping
20 18 179 (114) 6,4124E+12 5,23 3,35E+13 0,5 1 Class 5
c.277_317-
726delinsCCAT
full 
skipping
1 1 5 (5) 19,35 1,06 20,51 0,5 0,953504137 Class 4
c.316+1G>T full 
skipping
1 1 7 (4) 3,43 - 3,43 0,5 0,774439482 Class 3
c.316+2T>C full 
skipping
2 0 0 - - - - - -
c.316+4del full 
skipping
2 1 15 (10) 86,77 - 86,77 0,5 0,988606469 Class 4
c.316+5G>A full 
skipping
2 1 6 (5) 3,69 1,15 4,24 0,5 0,809128615 Class 3
c.316+5G>C full 
skipping
12 10 62 (41) 14544,25 2,94 36332,99 0,5 0,999976616 Class 5
Score total for 
all variants
full 
skipping
41 33 293 (194) 4,39E+25 0,5 1 Class 5
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MMC treatment, strongly suggesting that BRCA2 is not 
functional in these cells. These findings correlate with an 
increased cancer risk as calculated in our multifactorial 
likelihood analysis.
Our results suggest that this part of the protein is 
important for the DNA damage repair function of BRCA2. 
Among all the BRCA2 partners described above, an 
obvious candidate for the DNA repair defective function 
of the protein lacking exon 3 observed in this study is loss 
of the PALB2 binding site [24, 25, 40–43] (Figure 4). The 
region of interaction has been defined by crystallography 
for BRCA2 (amino acids 21–39 part of exon 3) and PALB2 
(WD40 motifs, amino acids 836–1186 from exon 6 to exon 
13, Figure 4B and 4C). The level of cancer risk associated 
to PALB2 pathogenic variants is known to be low in 
comparison to BRCA2 pathogenic variants, but enough 
to propose a clinical management of the familly contrary 
to other low risk genes, notably CHEK2 1100delC and 
ATM [44]. The importance of this interaction for the DNA 
repair function of BRCA2 has been highlighted in several 
studies [25, 45, 46]. In particular, Siaud et al showed that 
a truncated BRCA2 protein lacking the entire C-terminal 
DNA binding domain could partially restore the DSB 
repair function of BRCA2 only when the PALB2 binding 
site was intact. These results strongly suggest that PALB2 
interaction is important for the DSB repair function of 
BRCA2. BRCA2 and PALB2 cooperate in other related 
functions, such as the G2/M checkpoint control upon 
DNA damage [47]. In addition, in vitro, BRCA2 and 
PALB2 cooperate in stimulating RAD51-mediated D-loop 
formation, a critical step in HR [48]. Furthermore, PALB2 
is an integral component of the BRCA complex [49] in 
which PALB2 mediates the physical interaction between 
BRCA2 and the C-terminal region of BRCA1 (Figure 4A) 
[25, 50]. These three proteins also act together to protect 
stalled replication forks from excessive degradation [5]. It 
has recently been shown that both the RAD51 recruitment 
to DSBs and the replication fork protection function are 
impaired due to disruption of BRCA2-PALB2 interaction 
[45]. Based on the work on the truncated protein [46], 
the PALB2 binding site precludes the DSB function of 
BRCA2. Whether the replication protective function is 
also altered in the delta-exon 3 protein warrants further 
investigation.
The importance of the exon 3 and the effect on 
the risk in the absence of this domain should help to 
Figure 4: (A) Schematic representation of PALB2 domains and binding sites for its interacting partners (BRCA1 and BRCA2). (B) 
Interaction site with WD40 domain of the PALB2 protein and the exon 3 domain of the BRCA2 protein. Ribbon representation of the 
BRCA2-PALB2 complex (pdb ID: 3EU7). Domain WD40 of PALB2 is colored cyan and BRCA2 exon 3 is colored dark red. (C) Table of 
the interaction aminoacids for the EMSY and PALB2 proteins with the exon 3 domain of the BRCA2 protein.
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reconsider some interaction already described. Hugues-
Davies et al. found the EMSY gene to be amplified in 13% 
of all breast cancers and 17% of ovarian cancers (20% of 
cases of high-grade serous ovarian cancer [51]). EMSY 
was shown to be capable of silencing the transcription 
activation potential of a BRCA2 protein domain encoded 
by exon 3. Like BRCA2, EMSY also relocates to double-
strand break repair sites after DNA damage. These results 
reinforce the functional link between BRCA2 and EMSY. 
The BRCA2 inactivation through EMSY amplification 
might be important in the tumorigenesis of a substantial 
proportion of non-inherited sporadic breast cancer. Recent 
studies have shown that amplification of EMSY was also 
associated with other cancers such as prostate ans pancreatic 
cancers [52]. Overexpression of EMSY interferes with the 
potential activation domain of BRCA2 encoded by exon 
3 decreasing BRCA2 activity and resulting in a genomic 
instability phenotype as seen in BRCA2 deficient cells [22, 
53]. The absence of the exon-3 domain then mimics this 
action of EMSY and increase the risks.
Other functions have been assigned to the exon-
3 region., Smad3 have been described to be related to 
BRCA2 both as modifier gene for the risk and with a direct 
functional interaction with exon 3 [54]. Another team was 
shown an interaction between BRCA2 (residues 18-70) 
and hRPA (polypeptides 70 and 34) [55]. This interaction 
BRCA2-hRPA is detected in the presence or absence 
of DNA binding by RPA. This is in contrast to a report 
that the p53-hRPA interaction is abrogated if RPA was 
prebound to DNA. For those proteins, their relevance for 
the functional effect observed in this study is less obvious 
and would deserve more investigations.
Furthermore, this approach, to combine information 
from several families with different genetic alterations 
resulting in the same final impact on the transcript 
provided the statistical power to calculate the odds 
of causality for seven variants. In principle, the same 
approach could be applied to other in-frame exons, in 
which deletion would be expected to lead to an internally 
deleted protein such as exons 10, 11, 12 [56], 17, 19, 26 
and 27 of BRCA2 or in other cancer susceptibility genes.
CONCLUSIONS
This study demonstrates that full BRCA2 exon 3 
skipping is pathogenic, probably due to a defect in BRCA2 
DNA damage repair function, and provides convincing 
evidence that variant alleles producing only transcripts 
lacking exon 3 should be considered to be pathogenic.
MATERIALS AND METHODS
Patient recruitment and consent
Variants under study were identified after genetic 
testing of patients reporting family history consistent with 
a high risk of carrying a BRCA1 or BRCA2 pathogenic 
variant. In France, eligibility for testing is defined by 
the French “UNICANCER Genetic Group” (UGG) and 
Inserm guidelines [57]. The families from ENIGMA were 
recruited from many different countries according to each 
country’s specific guidelines in place [31].
Selected variants
Only variants suspected to result in complete 
deletion of BRCA2 exon 3 at the transcriptional level 
were selected for this study. The transcriptional impact 
was based on both the literature and on the results of 
functional analysis performed in the various participating 
laboratories. Intronic variants were validated by a 
dedicated minigene assay.
We evaluated eight BRCA2 variants resulting in a 
complete deletion of exon 3 (see Supplementary Table 
1 and Table 1): c.68-?_316+?del, c.156_157insAlu, 
c.277_317-726delinsCCAT [36] c.316+1G>T, 
c.316+2T>C, c.316+4del, c.316+5G>A, c.316+5G>C. 
Data from 39 families were therefore collected from 
France, Portugal, Denmark and Sweden. Genotype and 
clinical data from variant carriers and relatives were 
obtained via diagnostic clinical testing (for laboratories 
in which a variant was considered to be pathogenic) 
or otherwise via ethically approved research testing 
following informed consent of the participants. In France, 
the latter included recruitment via the COVAR study 
(https://clinicaltrials.gov/ct2/show/results/NCT01689584). 
Co-segregation data were obtained for 293 patients from 
the 33 families in this study (194 confirmed as carriers of 
the variant under study).
Cell-based minigene splicing assay
In order to evaluate the impact of the selected 
BRCA2 exon 3 variants on RNA splicing, we performed 
a functional assay based on the comparative analysis of 
the splicing pattern of wild-type (WT) and mutant reporter 
minigenes, as follows. Minigenes were prepared by using 
the pCAS2 vector [58, 59]. First, WT and mutant BRCA2 
genomic fragments c.68-165_c.316+225 (BRCA2 exon 3 
and part of the flanking introns) were PCR-amplified from 
patient genomic DNA by using forward primer B2Ex3_
Bam-F (5′- GACCGGATCCTTCGCAAGAGAATGGAT
TAATG-3′) and reverse primer B2Ex3_Mlu-R (5′- GAC
CACGCGTGGAGGGATGAAAGAGAACATTTAC-3′). 
Because patient’s DNA was not available for c.316+1G>T, 
we prepared the mutant DNA segment by site-directed 
mutagenesis using the two-stage overlap extension PCR 
method [Ho et al, 1989] and the pCAS2-BRCA2e3.WT 
construct as a template. After digestion with BamHI and 
MluI, the PCR products were inserted into the cloning 
sites of the reporter plasmid pCAS2, yielding the three-
exon hybrid minigenes pCAS2-BRCA2e3. All constructs 
were sequenced to ensure that no unwanted mutations 
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had been introduced into the inserts during the PCR or 
cloning process. Next, WT and mutant minigenes (400 
ng/well) were transfected in parallel into HeLa cells 
grown at ~70% confluence in 12-well plates using the 
FuGENE 6 transfection reagent (Roche Applied Science). 
HeLa cells obtained from ATCC were cultivated in 
Dulbecco’s modified Eagle medium (Life Technologies) 
supplemented with 10% fetal calf serum in a 5% CO2 
atmosphere at 37°C. Twenty-four hours later, total RNA 
was extracted using the NucleoSpin RNA II kit (Macherey 
Nagel) according to the manufacturer’s instructions, 
and the minigenes’ transcripts were analysed by semi-
quantitative RT-PCR (30 cycles of amplification) in a 
25 μl reaction volume by using the OneStep RT-PCR 
kit (Qiagen), 200 ng total RNA and minigene specific 
primers (KOI-F 5′-TGACGTCGCCGCCCATCAC-3′ and 
pCAS2R 5′-ATTGGTTGTTGAGTTGGTTGTC-3′). RT-
PCR products were separated by electrophoresis on 2.5% 
agarose gels containing ethidium bromide and visualized 
by exposure to ultraviolet light under saturating conditions 
using the Gel Doc XR image acquisition system (Bio-
Rad), followed by gel-purification and sanger sequencing 
for proper identification of the minigene’s transcripts. 
Finally, splicing events were quantitated by performing 
equivalent fluorescent RT-PCR reactions followed by 
capillary electrophoresis on an automated sequencer 
(Applied Biosystems) using 500 ROX™ Size Standard 
(Applied Biosystems) and computational analysis by using 
the GeneMapper v5.0 software (Applied Biosystems).
Bioinformatics predictions of splicing alterations
For each of the selected intronic variants, in silico 
predictions of their potential effects on splice sites 
were obtained by using the following in silico tools: 
SpliceSiteFinder-like (SSF, http://www.interactive-
biosoftware.com), MaxEntScan (MES, http://genes.mit.
edu/burgelab/maxent/Xmaxentscan_scoreseq.html) [60], 
NNSplice (NNS), GeneSplicer (GS) and Human Splicing 
Finder (HSF, http://www.umd.be/HSF/) [61]. These 
algorithms were simultaneously interrogated by using 
the integrated software Alamut (Interactive Biosoftware, 
http://www.interactive-biosoftware.com).
Segregation analyses, multifactorial likelihood 
analysis and calculation of posterior probability 
of pathogenicity
Segregation analysis can be used to determine 
an odds or likelihood ratio quantifying the probability 
that a variant is linked to breast and/or ovarian cancer 
more than expected by chance. In a family in which 
most individuals carrying a particular variant develop 
breast/ovarian cancer, there is a strong likelihood that 
the variant causes the cancer phenotype. For a given 
variant, the product of the individual Bayes factors 
over the relevant families generates a likelihood ratio 
that quantifies the association with the disease [62]. In 
addition to segregation information as a direct measure 
of disease causality in families, the overall evaluation of 
causality can be calculated using multifactorial likelihood 
analysis [63] that includes additional information. For 
each variant, the likelihood ratio derived from co-
segregation analysis was combined with other sources 
of data (family history, pathology data, etc.) to generate 
an overall likelihood score of causality. Information 
on segregation was available for all other families, 
and likelihood ratios (LRs) based on tumor pathology 
were available for a subset of variants. Multifactorial 
analysis was conducted using the methods described 
in Walker et al [64] which incorporates likelihoods for 
segregation and tumor pathology [65]. As previously 
described [63], probabilities were derived for each 
component under the assumption that each factor was 
statistically independent, the individual likelihood ratios 
were multiplied to calculate an overall multifactorial 
likelihood ratio, and Bayes factor analysis was then 
used to calculate a posterior probability that the variant 
was pathogenic from the multifactorial likelihood ratio 
and the prior probability. Given the knowledge that all 
variants resulted in the same aberration at the molecular 
level, and fact that the research question was to assess the 
clinical relevance of this molecular aberration (whether 
or not this aberration is pathogenic), all variants were 
assigned a prior probability of 0.5 [66, 67].
Variants were classified according to the criteria 
defined by Plon et al. [33], namely: Class 1: not 
pathogenic posterior probability (pp) 0.001; class 2: likely 
not pathogenic pp 0.001–0.049; Class 3: uncertain pp 
0.05–0.949; Class 4: likely pathogenic pp 0.95–0.99; Class 
5: pathogenic pp 0.99.
Clonogenic survival assay
Cloning of the deletion of exon 3 from BRCA2 
into GFP-MBP-BRCA2 was obtained by PCR from a 
fragment synthesized from a patient carrying the deletion 
using the following primers: 5’ TAACCGGTACCCA
GCGGCCGCCCTATTGGATCCAAAGAG 3’ and 5’ 
CATATCAGGATCCACCTCAGCTCCTAGAC 3’. The 
insert was cloned into NotI and BbvCI sites of the GFP-
MBP-BRCA2. All constructs were verified by DNA 
sequencing.
Brca2-deficient hamster cells (VC8) were 
transfected with human GFP-MBP-tagged full-length 
BRCA2, BRCA2 Δ exon 3 or known pathogenic missense 
BRCA2 variant D2723H (c.8167G>C, exon 18) cDNA 
expression constructs using Turbofect (Thermo Fisher 
Scientific) according to the manufacturer’s specifications. 
Cell populations were selected in HAM’s F10 media 
(10% FBS) containing 1 mg/ml G418 (Sigma-Aldrich). 
After one week in selection media, the cell population 
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was seeded for clonogenic survival assay, incubated 
overnight and treated with Mitomycin C (Sigma-Aldrich) 
at concentrations of 0.25, 0.5 and 1.0 μM in serum-
free HAM’s F10 media. Cells were treated for 1 h with 
the indicated concentrations of MMC, then washed, 
trypsinized, serially diluted and seeded in triplicates 
into 6-well plates. After 9 days of culture the cells were 
washed and stained with 1% crystal violet. Plates were 
dried overnight and colonies were counted to determine 
the survival fraction for each MMC concentration.
Immunodetection of BRCA2
To verify protein expression, a fraction of the cells 
was harvested and lysed in lysis buffer containing 50 mM 
Hepes (pH 7.5), 250 mM NaCl, 5 mM EDTA, 1% NP-40, 
1 mM dithiothreitol (DTT), 1 mM PMSF, and Protease 
Inhibitor Cocktail (Roche). GFPMBP-BRCA2 protein was 
detected from GFP-trap (ChromoTek) immunoprecipitates 
by immunoblotting with GFP antibody (Sigma G1544, 
1:500).
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